1. Shalev N, van Sighem AI, Bezemer DO, Juuriaans S, et al.
   Cabotegravir and rilpivirine resistance-associated mutations among people with newly diagnosed HIV-1 in the Netherlands.
   AIDS 2026.
   


2. Awwad A, Das Adhikari U, Burdo TH, Baak S, et al.
   Pitavastatin effect on enterocyte injury markers in an ART treated HIV population: Insights from REPRIEVE.
   AIDS 2026.
   


3. Gervasoni C, Cossu MV, Giacomelli A, Iannone V, et al.
   Blood pressure control in people with HIV and established atherosclerotic cardiovascular disease: a real-world descriptive analysis.
   AIDS 2026;40:1216-1217.
   


4. Titanji BK, Dabbs-Brown A, Mather JT, Hui Q, et al.
   Genome-wide association study of cardiovascular disease in people with HIV from the Million Veteran Program (MVP).
   AIDS 2026;40:1212-1215.
   


5. Lapadula G, Soria A, Puoti M, Bonfanti P, et al.
   Occult hepatitis B and risk of reactivation following switch to non-hepatitis B virus-active antiretroviral therapy in people with HIV.
   AIDS 2026;40:1053-1066.
   


6. Votsika V, Mohan S, Phillips A, Colbourn T, et al.
   The Potential Impact of Reduced Donor Funding for HIV Programs on Malawi's Disease Burden.
   AIDS 2026.
   


7. Ge Z, Liu D, Zhong H, Niu Z, et al.
   Near Full-Length Genome Characterization of a Novel Second-Generation HIV-1 CRF01_AE/CRF07_BC Recombinant Identified in an MSM Individual in Guizhou, China.
   AIDS Res Hum Retroviruses 2026.
   


8. Horberg M, Thompson M, Agwu A, Colasanti J, et al.
   Clarification to HIVMA/IDSA HIV Primary Care Guidance Immunization Recommendations.
   Clin Infect Dis 2026.
   


9. Feng X, Nakigozi G, Patel EU, Kennedy CE, et al.
   HIV seroprevalence, incidence, and viral suppression among Ugandan female bar workers: a population-based study.
   J Acquir Immune Defic Syndr 2026.
   


10. Torgersen J, Newcomb CW, Carbonari DM, Rentsch CT, et al.
    Evaluating Associations Between Cumulative Use of Chronic Liver Injury-Inducing Antiretroviral Therapy and Hepatocellular Carcinoma, By Chronic Liver Disease Status.
    J Acquir Immune Defic Syndr 2026.
    


11. Bhardwaj S, Mugisha J, Magembe J, Eram G, et al.
    Men's preferences for HIV self-test distribution strategies in Uganda: A discrete choice experiment.
    J Acquir Immune Defic Syndr 2026.
    


12. Tollefson D, Lankowski A, Dasgupta S, Kazmirak C, et al.
    Preferences for HIV testing among partners of transgender women in Lima, Peru: a discrete choice experiment.
    J Acquir Immune Defic Syndr 2026.
    


13. Rivera AV, Pathela P, Rodriguez K, Edelstein Z, et al.
    Trends in sexually transmitted infections by PrEP use among cisgender men who have sex with men in New York City, 2014-2023.
    J Acquir Immune Defic Syndr 2026.
    


14. Woldemeskel M, Unternaher J, Munger O, Williams T, et al.
    Birth and Infant Growth Outcomes Following Prenatal Exposure to Bictegravir.
    J Acquir Immune Defic Syndr 2026.
    


15. Yang C, Shi L, Wei C, Martinez O, et al.
    Mapping risk and opportunity: A space-based affiliation network analysis of physical and virtual spaces among high risk men.
    J Acquir Immune Defic Syndr 2026.
    


16. Bien-Gund C, Gross R, Williams J, Brady KA, et al.
    Lower self-efficacy and lower PrEP stigma predict telePrEP preferences among HIV self-testers.
    J Acquir Immune Defic Syndr 2026.
    


17. Jeetoo M, Yeo YR, Charles DL, Moll AP, et al.
    Cost-effectiveness of reducing HIV infections through screening and treating alcohol use and depression in KwaZulu-Natal, South Africa: a mathematical modeling study.
    J Acquir Immune Defic Syndr 2026.
    


18. Fahey CA, Whitney BM, Drumright LN, Mehta SH, et al.
    Association between housing instability and HIV care outcomes among people with HIV in the United States.
    J Acquir Immune Defic Syndr 2026.
    


19. Forer R, Clark JL, Gutierrez J, Segura E, et al.
    Unpacking "High-Risk": A Latent Class Analysis of Sexual Partnership Patterns and HIV Transmission Risk Among Gay, Bisexual, and other Men who have Sex with Men in Peru.
    J Acquir Immune Defic Syndr 2026.
    


20. van der Molen J, Tlhaku K, Lewis L, Sookrajh Y, et al.
    Earlier referral to differentiated antiretroviral therapy delivery at six months after initiation: a retrospective cohort study in KwaZulu-Natal, South Africa.
    J Acquir Immune Defic Syndr 2026.
    


21. Offorjebe OA, Ochola E, Ngila B, Kinuthia J, et al.
    Eligibility and Acceptability of Same-Day HIV Pre-Exposure Prophylaxis Initiation During Emergency Care Encounters in Nairobi, Kenya: A Cross-Sectional Study.
    J Acquir Immune Defic Syndr 2026.
    


22. Rosen JG, Offorjebe OA, Ngila B, Kinuthia J, et al.
    Anticipated Determinants and Strategies Supporting Same-Day HIV Pre-Exposure Prophylaxis Implementation During Emergency Care Encounters in Kenya: A Qualitative Study.
    J Acquir Immune Defic Syndr 2026.
    


23. Lewis L, Sookrajh Y, van der Molen J, Khubone T, et al.
    Indirect effects of HIV differentiated service delivery programmes on quality of clinic care: a retrospective cohort study of clients starting antiretroviral therapy.
    J Acquir Immune Defic Syndr 2026.
    


24. Appa A, Javanbakht M, Spinelli M, Heise MJ, et al.
    Hair Testing to Detect Long-term Methamphetamine Use in People Living with and without HIV.
    J Acquir Immune Defic Syndr 2026.
    


25. Morsica G, Lolatto R, Diotallevi S, Svicher V, et al.
    Hepatitis B Reactivation in People with HIV After Switching to a 2-Drug Anti-HBV Sparing Regimen.
    J Acquir Immune Defic Syndr 2026.
    


26. Chengsupanimit T.
    A Tribute to Our Mentors.
    J Infect Dis 2026.
    


27. Bermejo-Jambrina M, Pauzuolis M, Kimpel J, Gerold G, et al.
    Double trouble: how co- and superinfections shape viral dynamics and host responses.
    J Virol 2026.
    


28. Falconer J, Bekker LG, Jarvis JN.
    Long-Acting Treatment and Advanced HIV Disease - Addressing a Public Health Priority.
    N Engl J Med 2026.
    


29. Conradie F, Badat T, Poswa A, Rajaram S, et al.
    A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis.
    N Engl J Med 2026;394:2429-2439.
    


30. Wei W, Zhou Y, Ma Y, Yang Z, et al.
    Generation and evaluation of an EcoHIV mouse model to study HIV-1 integration and expression.
    Virology 2026;623:110991.
    


31. Waris A, Kavanagh MM.
    Action for a healthier global tax system.
    BMJ 2026;393:e343297.
    

Display articles in

• Abstract format